.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FA02_Ofatumumab.Ofatumumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FA02_Ofatumumab.Ofatumumab| name: | Ofatumumab |
| ATC code: | L01FA02 | route: | intravenous |
| n-compartments | 2 |
Ofatumumab is a fully human monoclonal antibody that targets the CD20 molecule on B lymphocytes, leading to cell lysis predominantly through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. It is approved for the treatment of chronic lymphocytic leukemia (CLL) and is also approved (under a different formulation and dosing) for relapsing forms of multiple sclerosis (MS).
Pharmacokinetics were evaluated in adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) after intravenous infusion. Population pharmacokinetic analysis was performed for multiple doses.
Struemper, H, et al., & Jewell, RC (2014). Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. Journal of clinical pharmacology 54(7) 818–827. DOI:10.1002/jcph.268 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24443277
Ogura, M, et al., & Hotta, T (2013). Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Japanese journal of clinical oncology 43(5) 466–475. DOI:10.1093/jjco/hyt022 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23456745